- Email: [email protected]
Headworks introduces the ‘Eliminator’
NEWS Editorial Office: Elsevier Advanced Technology, P O Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843239 Fax: +44 (0)1865 843971 E-mail: [email protected]
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Millipore’s revenue growth rate slows
Headworks introduces the ‘Eliminator’
Millipore’s revenue growth rate in the third quarter of 2004 was lower than that achieved in the first half of the year. Fran Lunger, Millipore’s Chief Executive Office (CEO), notes: ‘This was due to a combination of a difficult comparison with an unusually strong third quarter last year, the uneven timing of new drug ramp-ups and manufacturing, and a slowdown of sales to pharmaceutical companies in Europe and Japan.’ The company, which is based in Billerica, Massachusetts, posted thirdquarter revenues of $211 million – up 5% from the figure recorded for the equivalent period of 2003. For the first nine months of 2004 revenues rose 13%. In constant currency terms, revenues were up 1% for the quarter and 7% for the year to date. Earnings per share in the third quarter of 2004 were $0.50 – essentially the same as the third quarter of 2003. Earnings results for the third quarter include a $0.02 per share expense associated with the transition of the CEO announced in the second quarter. Lunger continues: ‘By market, third-quarter revenues in biotechnology were down by 1% in constant currency terms compared with 2003. There was a single sale of more than $7 million in chromatography media in the third quarter of 2003, for a biotechnology drug process validation that negatively affected quarterto-quarter growth. The business remains fundamentally strong, and is our highest growth opportunity over the next few years.’ Lunger says that growth in life sciences, in constant currency terms, was 7% in the third quarter, compared with the corresponding period of 2003. Revenue growth in other biosciences was 1%, with some weakness in Europe and Japan because of a slowdown in sales to pharmaceutical companies and laboratory funding issues.
US-based water and wastewater treatment equipment OEM Headworks Inc has introduced a screening system for use in membrane bioreactor system applications. The ‘Eliminator’ is installed upstream of the finer filtration systems, and is highly efficient, says the company. The Eliminator is a type of screen commonly referred to as a ‘bandscreen’ or ‘center-flow’ screen. The stainless elements form a continuous band, which travels parallel within the channel. Water enters through the center of the screen, turns through a 90° angle, passes through the stainless steel sieve elements, and exits through the sides of the unit. Screenings are captured by the elements and are carried to a discharge point. The unit’s design and construction eliminates carry-over, reduces upstream floatables and requires very little maintenance, according to Headworks.
Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, Fax: +1 781 533 3110, www.millipore.com
Contact: Headworks Inc, 11011 Richmond, Suite 900, Houston, TX 77042, USA. Tel: +1 713 647 6667, Fax: + 713 647 0999, www.headworksusa.com
Ionics reports stronger results Massachusetts-based Ionics Inc has reported strong results for the three-month and nine-month periods ended 30 September 2004. Third-quarter revenues this year totalled $118.1 million, compared with $87.7 million for the corresponding period of 2003. The company posted net income of $0.9 million, compared with a net loss of $22.0 million for the third quarter of 2003. Revenues for the first nine months of 2004 amounted to $349.6 million, compared with $251.5 million for the first nine months of 2003. Ionics recorded a
net loss of $5.4 million for the first nine months of 2004, compared with a net loss of $26.4 million for the equivalent period in 2003. Also included in the company’s financial results are the consolidated results of the Ecolochem Group, which was acquired during February, and Desalination Co of Trinidad and Tobago Ltd (Desalcott) – the company’s joint venture in Trinidad. Ecolochem’s revenues for the quarter and the first nine months were $22.3 million and $58.5 million, respectively, while Desalcott revenues totalled $7.4 million and $21.8 million, respectively. Commenting on the results for the quarter, Chief Executive Officer Doug Brown says: ‘The company’s financial results demonstrate the impact of the numerous restructuring initiatives launched over the past year. We are continuing to implement programs designed to further increase profitability.’ Contact: Ionics Inc, 65 Grove Street, Watertown, MA 02471-9131, USA. Tel: +1 617 926 2500, Fax: +1 617 926 4304, www.ionics.com
Watts Premier completes EPA ETV program Watts Premier, a subsidiary of Watts Water Technologies Inc, has completed microbial contamination testing of one of its product lines under the US Environmental Protection Agency (EPA) Environmental Technology Verification (ETV) Program. Watts Premier’s five-stage reverse osmosis (RO) systems were tested for the removal of microbial contaminants in drinking water. The company, which is based in Phoenix, Arizona, claims that the use of its RO systems will significantly reduce the risk of exposure to water-borne bacteria and virus, should there be a contamination within municipal or private water distribution systems. Shannon Murphy, Vice President of Municipal Programs at Watts, says: ‘We are pleased
Membrane Technology December 2004
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Millipore’s revenue growth rate slows
Headworks introduces the ‘Eliminator’
Millipore’s revenue growth rate in the third quarter of 2004 was lower than that achieved in the first half of the year. Fran Lunger, Millipore’s Chief Executive Office (CEO), notes: ‘This was due to a combination of a difficult comparison with an unusually strong third quarter last year, the uneven timing of new drug ramp-ups and manufacturing, and a slowdown of sales to pharmaceutical companies in Europe and Japan.’ The company, which is based in Billerica, Massachusetts, posted thirdquarter revenues of $211 million – up 5% from the figure recorded for the equivalent period of 2003. For the first nine months of 2004 revenues rose 13%. In constant currency terms, revenues were up 1% for the quarter and 7% for the year to date. Earnings per share in the third quarter of 2004 were $0.50 – essentially the same as the third quarter of 2003. Earnings results for the third quarter include a $0.02 per share expense associated with the transition of the CEO announced in the second quarter. Lunger continues: ‘By market, third-quarter revenues in biotechnology were down by 1% in constant currency terms compared with 2003. There was a single sale of more than $7 million in chromatography media in the third quarter of 2003, for a biotechnology drug process validation that negatively affected quarterto-quarter growth. The business remains fundamentally strong, and is our highest growth opportunity over the next few years.’ Lunger says that growth in life sciences, in constant currency terms, was 7% in the third quarter, compared with the corresponding period of 2003. Revenue growth in other biosciences was 1%, with some weakness in Europe and Japan because of a slowdown in sales to pharmaceutical companies and laboratory funding issues.
US-based water and wastewater treatment equipment OEM Headworks Inc has introduced a screening system for use in membrane bioreactor system applications. The ‘Eliminator’ is installed upstream of the finer filtration systems, and is highly efficient, says the company. The Eliminator is a type of screen commonly referred to as a ‘bandscreen’ or ‘center-flow’ screen. The stainless elements form a continuous band, which travels parallel within the channel. Water enters through the center of the screen, turns through a 90° angle, passes through the stainless steel sieve elements, and exits through the sides of the unit. Screenings are captured by the elements and are carried to a discharge point. The unit’s design and construction eliminates carry-over, reduces upstream floatables and requires very little maintenance, according to Headworks.
Contact: Millipore Corporation, 290 Concord Road, Billerica, MA 01821, USA. Tel: +1 978 715 4321, Fax: +1 781 533 3110, www.millipore.com
Contact: Headworks Inc, 11011 Richmond, Suite 900, Houston, TX 77042, USA. Tel: +1 713 647 6667, Fax: + 713 647 0999, www.headworksusa.com
Ionics reports stronger results Massachusetts-based Ionics Inc has reported strong results for the three-month and nine-month periods ended 30 September 2004. Third-quarter revenues this year totalled $118.1 million, compared with $87.7 million for the corresponding period of 2003. The company posted net income of $0.9 million, compared with a net loss of $22.0 million for the third quarter of 2003. Revenues for the first nine months of 2004 amounted to $349.6 million, compared with $251.5 million for the first nine months of 2003. Ionics recorded a
net loss of $5.4 million for the first nine months of 2004, compared with a net loss of $26.4 million for the equivalent period in 2003. Also included in the company’s financial results are the consolidated results of the Ecolochem Group, which was acquired during February, and Desalination Co of Trinidad and Tobago Ltd (Desalcott) – the company’s joint venture in Trinidad. Ecolochem’s revenues for the quarter and the first nine months were $22.3 million and $58.5 million, respectively, while Desalcott revenues totalled $7.4 million and $21.8 million, respectively. Commenting on the results for the quarter, Chief Executive Officer Doug Brown says: ‘The company’s financial results demonstrate the impact of the numerous restructuring initiatives launched over the past year. We are continuing to implement programs designed to further increase profitability.’ Contact: Ionics Inc, 65 Grove Street, Watertown, MA 02471-9131, USA. Tel: +1 617 926 2500, Fax: +1 617 926 4304, www.ionics.com
Watts Premier completes EPA ETV program Watts Premier, a subsidiary of Watts Water Technologies Inc, has completed microbial contamination testing of one of its product lines under the US Environmental Protection Agency (EPA) Environmental Technology Verification (ETV) Program. Watts Premier’s five-stage reverse osmosis (RO) systems were tested for the removal of microbial contaminants in drinking water. The company, which is based in Phoenix, Arizona, claims that the use of its RO systems will significantly reduce the risk of exposure to water-borne bacteria and virus, should there be a contamination within municipal or private water distribution systems. Shannon Murphy, Vice President of Municipal Programs at Watts, says: ‘We are pleased
Membrane Technology December 2004